Abstract:Background and objectives: Globally, a number of countries have developed guidelines that describe the design and conduct of economic evaluations as part of health technology assessment (HTA) or pharmacoeconomic analysis for decision making. The current scoping review was undertaken with an objective to summarize the recommendations made on methods of economic evaluation by the national healthcare economic evaluation (HEE) guidelines. Methodology: A comprehensive search was undertaken in the website repositories of the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) and Guide to Economic Analysis and Research (GEAR), and websites of national HTA agencies and ministries of health of individual countries. All guidelines in the English language were included in this review. Data were extracted with respect to general and methodological characteristics, and a descriptive analysis of recommendations made across the countries was undertaken. Results: Overall, our review included 31 national HEE guidelines, published between 1997 and August 2020. Nearly half (45%) of the guidelines targeted the evaluation of pharmaceuticals. The nature of the guidelines was either mandatory (31%), recommendatory (42%), or voluntary (16%). There was a substantial consensus among the guidelines on several key principles, including type of economic evaluation (cost-utility analysis), time horizon of the analysis (long enough), health outcome measure (quality-adjusted life-years) and use of sensitivity analyses. The recommendations on study perspective, comparator, discount rate and type of costs to be included (particularly the inclusion of indirect costs) varied widely. Conclusion: Despite similarity in the overall processes, variation in several recommendations given by various national HEE guidelines was observed. This is perhaps unsurprising given the differences in the health systems and financing mechanisms, capacity of local researchers, and data availability. This review offers important lessons and a starting point for countries that are planning to develop their own HEE guidelines.

Health Outcome Measurement in Pharmacoeconomic Evaluation

Cost Definition in Pharmacoeconomic Evaluation and Existing Controversy

International Experience of Pharmacoeconomic Evaluation in Health Decision-making

Study of the Related Problems in the Application of the Cost- Effectiveness Analysis in Pharmacoeconomics

Quality of Pharmacoeconomic Research in China: A Systematic Review

Guidelines for Pharmacoeconomic Studies

A Critical Review of Chinese Pharmacoeconomics Studies in the Last Five Years.

Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions: An ISPOR Special Interest Group Report

Health Economic Methods: Cost-Minimization, Cost-Effectiveness, Cost-Utility, and Cost-Benefit Evaluations

Establishment of Drug Value Indicators System

Systems analysis and evaluation of Chinese pharmacoeconomic literatures over ifve years

A knowledge-attitude-practice investigation of pharmacoeconomics in different stakeholders

National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison

Outcomes of guidelines from health technology assessment organizations in community-based primary care: a systematic mixed studies review

Assessment of the quality of pharmacoeconomic evaluation literature in China

Budget Impact Analysis and Cost-effectiveness Analysis

A comparative study of international health care performance assessment frameworks

Systematic Evaluation of Pharmacoeconomic Literatures on Domestic Digestive System Diseases

A Scoping Review of Tools and Techniques on Evaluating Population Health and Healthy Life Expectancy

Review of Efficiency Evaluation Methodology

Application of Health Insurance Data in Pharmacoeconomics Evaluation--International Experience and Related Advices